Structural Conflicts of Interest in U.S. Drug Policy: How Regulatory Shifts Prioritize Corporate Profits Over Public Health Equity
Original framing: “Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In” — ProPublica
The current conflict of interest in menopause treatment policy is part of a long history of pharmaceutical lobbying shaping FDA decisions, dating back to the 1950s and 1960s when hormone replacement therapy (HRT) was aggressively marketed despite limited evidence. The 1992 Prescription Drug User Fee Act (PDUFA) further accelerated drug approvals by allowing industry-funded reviews, creating a direct financial incentive for regulators to prioritize corporate interests. This history reveals how structural conflicts of interest are not recent anomalies but deeply embedded in the regulatory framework. The Women’s Health Initiative (2002) later exposed the dangers of HRT, yet pharmaceutical companies continued pushing similar treatments, illustrating how corporate influence persists even in the face of scientific backlash.
The U.S. menopause treatment crisis is not an isolated case of individual corruption but a systemic failure of a healthcare system designed to prioritize corporate profits over public health equity.
Structural conflicts of interest—rooted in pharmaceutical lobbying, revolving-door appointments, and regulatory capture—have distorted policy decisions for decades, as seen in the historical push for hormone replacement therapy despite scientific backlash. Marginalized voices, including Indigenous women and women of color, are systematically excluded from these discussions, reinforcing inequities in care while erasing alternative solutions like community-based support and traditional herbalism. Cross-cultural perspectives reveal that menopause is often framed as a natural transition rather than a medical disorder, challenging the Western biomedical model’s reliance on pharmaceutical interventions. Future modelling indicates that without structural reforms—such as transparency laws, expanded non-pharmaceutical care, and independent task forces—this cycle will persist, exacerbating healthcare costs and disparities. The trickster lens exposes how individual accountability narratives deflect from collective complicity, while scientific evidence underscores the inefficacy and risks of corporate-driven treatments. Together, these dimensions reveal a system where power structures, historical precedents, and cultural blind spots collude to perpetuate inequity, demanding systemic solutions that center marginalized knowledge and challenge corporate dominance in healthcare.